Reuters Examines Challenges Of Bringing First Malaria Vaccine To Market

Reuters: Caveats, costs, and complexities shadow first malaria vaccine
“…Backed by billionaire philanthropist Bill Gates and developed by GlaxoSmithKline, the vaccine — called RTS,S or Mosquirix — is being assessed by regulators and global health authorities. Granting it a license and recommending it for rollout in sub-Saharan Africa, where malaria kills one child almost every minute, ought to be a no-brainer. But Mosquirix is hampered by caveats, complexities, and cost implications that threaten to make its arrival on the global health stage more of a problem than a solution, possibly not just for malaria but for vaccines in general…” (Kelland, 7/14).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.